July 28, 2020 - Sekisui (Burlington, MA) announced the decision to invest £14.4 million (about U.S. $18.7 million) in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent, UK. The expansion is expected to be completed by the second half of 2022. The facility expansion and cGMP upgrades will enable Sekisui to take on … [Read more...]
Sekisui Diagnostics announces FDA clearance, CLIA Waiver of OSOM Ultra Plus Flu A&B Test
Sekisui Diagnostics announced it received FDA clearance and CLIA Waiver of the OSOM Ultra Plus Flu A&B Test intended for the qualitative detection of influenza type A and type B nucleoprotein antigens directly from nasal or nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection. According tot he company, the test utilizes … [Read more...]